News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...
Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.
Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...
Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside ...
Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...
(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...
According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results